Kumazawa H, Ishikawa M, Rei S, Saito H
Dept. of General Surgery and Digestive Surgery, Kosei Chuo General Hospital.
Gan To Kagaku Ryoho. 1987 Dec;14(12):3329-35.
This study was carried out with 48 patients received surgery, i.e., 23 stomach cancer, 8 colon cancer, 6 rectal cancer, 9 breast cancer etc. Patients in group A received UFT in combination with OK-432. Each of UFT or OK-432 was given to the patients in groups B or C, respectively. Changes in the skin reaction to Su-PS were measured before and after dosing, and concentrations of Tegafur and 5-FU in serum and tumor tissues were determined after administration. Analysis of the skin reaction to Su-Ps revealed that patients with positive skin reaction before surgery in group A didn't manifest depression due to sensitization by UFT therapy. Although average values of the skin reaction after dosing were slightly lower compared to those before dosing in group B, sensitization was effective. Values of the skin reaction after dosing were significantly (p less than 0.05) high compared to those before dosing in groups A and C. Concentrations of Tegafur and 5-FU in serum reached to the peak 2 hr later and were maintained high enough to expect clinical responses even at 4 hr after administration in groups A and B. Especially there was not a significant difference between groups A and B in tumor tissue levels of 5-FU, and a high effective concentration was obtained. Combination therapy of UFT with OK-432 exhibited no significant interaction between them in adjuvant immuno-chemotherapy, and satisfactory results were expected in clinical cures.
本研究对48例接受手术的患者进行,即23例胃癌、8例结肠癌、6例直肠癌、9例乳腺癌等。A组患者接受优福定(UFT)联合溶链菌制剂(OK - 432)治疗。B组和C组患者分别单独给予优福定或溶链菌制剂。给药前后测量对链球菌变应原提取物(Su - PS)的皮肤反应变化,并在给药后测定血清和肿瘤组织中替加氟和5 - 氟尿嘧啶的浓度。对Su - PS皮肤反应的分析表明,A组术前皮肤反应阳性的患者未因优福定治疗致敏而出现反应降低。虽然B组给药后皮肤反应的平均值比给药前略低,但致敏是有效的。与给药前相比,A组和C组给药后皮肤反应值显著升高(p小于0.05)。A组和B组血清中替加氟和5 - 氟尿嘧啶的浓度在给药后2小时达到峰值,甚至在给药后4小时仍维持在足以预期临床反应的高水平。尤其是A组和B组之间5 - 氟尿嘧啶的肿瘤组织水平无显著差异,并获得了高有效浓度。优福定与OK - 432的联合治疗在辅助免疫化疗中未表现出显著的相互作用,有望在临床治疗中取得满意的结果。